Precipio, Inc. (PRPO) Stock: Here’s What’s Happening


Precipio, Inc. (PRPO) is gaining in the market in today’s trading session. The stock, focused in the biotech space, is currently priced at $0.28 after a move up of 5.66% so far in today’s session. As it relates to biotechnology stocks, there are several factors that have the ability to cause movement in the market. One of the most common is news. Here are the most recent stories surrounding PRPO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-09-19 09:15AM Precipio Identifies Manufacturer for its IV-Cell Media
Apr-03-19 07:38AM Precipios HemeScreen Adopted by Methodist Health
Mar-27-19 07:47AM Precipio Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing
Mar-11-19 08:45AM Precipio CEO Issues Shareholder Update Letter
Mar-05-19 07:40AM Continued ICP Orders From Japanese Customers

Nonetheless, any time investors are making an investing decision, prospective investors should take a look at far more than news, this is especially the case in the generally speculative biotech sector. Here’s what’s happening in regard to Precipio, Inc..

How PRPO Has Been Trending

While a move up on a single session, like the move that we’re seeing from Precipio, Inc. may cause excitement in some investors, a single session move by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It’s always important to look into trends beyond a single trading day. As it relates to PRPO, here are the movements that we have seen:

  • Past 7 Days – In the past five trading sessions, PRPO has generated a change in value that amounts to 86.79%.
  • Past Month – The monthly returns from Precipio, Inc. comes to 80.76%.
  • Past Three Months – Throughout the past quarter, the company has produced a ROI that comes to 7.69%
  • Past 6 Months – Throughout the past six months, investors have seen a performance of -12.50% from the company.
  • Year To Date – Since the the last trading session of last year PRPO has generated a return on investment of 81.82%.
  • Annually – Finally, throughout the last full year, we have seen a change amounting to -42.81% from PRPO. Throughout this period, the stock has sold at a high of -58.82% and a low price of 154.31%.

Notable Ratios

Digging into various key ratios associated with a stock can give prospective traders an understanding of just how dangerous and/or potentially profitable a an investment option may be. Here are a few of the important ratios to look at when looking at PRPO.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors believe that the value of the stock is headed for declines. Throughout the sector, biotechnology stocks can carry a higher short ratio. However, we also see a lot of short squeezes in the sector. Nonetheless, as it relates to Precipio, Inc., it’s short ratio clocks in at 0.21.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure If a company is able to pay its debts as they mature with only quick assets or current assets. In the biotechnology space, several companies are reliant on the continuation of investor support, the quick and current ratios can be bad. However, several better companies in the biotechnology sector do have great quick and current ratios. As far as PRPO, the quick and current ratios come to 0.10 and 0.10 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets that are owned by the company. as it relates to Precipio, Inc., that ratio is 0.40.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the value of the company’s stock. Many clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotech sector, this is an important ratio to look into. In this case, the cash to share value ratio works out to 0.00.

What Analysts Think About Precipio, Inc.

While it’s never a smart idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a good idea to consider their thoughts in order to validate your own thoughts when it comes to making an investment decision in the biotechnology industry. Here are the most recent moves that we’ve seen from analysts with regard to PRPO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Show Me The Big Money

One thing that I have learned so far in my short period on Earth is that smart investors tend to follow the moves made by big money. In other words, investors that want to play it relatively safe will watch moves made by institutional investors as well as those on the inside. So, where is the big money as it relates to PRPO? Here’s what’s going on:

  • Institutional Investors – As it stands now, institutional investors own 1.20% of the company. However, it is important to consider that institutional ownership has seen a move of -0.20% over the past quarter.
  • Insiders – When it comes to insiders, those close to the company currently hold 1.80% of the company. Insider ownership of the company has moved 0 over the past quarter.

A Look At Share Counts

Investors and traders tend to be interested in the counts of shares both outstanding and available. As it relates to Precipio, Inc., there are currently 40.67M with a float of 40.67M. These numbers mean that out of the total of 40.67M shares of PRPO that are out there today, 40.67M are available to be traded on the public market.

I also like to pay attention to the short float. After all, when a high percentage of the float available for trading is sold short, the overall feeling among traders is that the company is going to lose value. In regard to PRPO, the percentage of the float that is shorted currently sits at 2.91%. Most investors would say that a high short percent of the float would be considered to be anything over 40%. Nonetheless, I’ve found that a short ratio over 26% is probably going to be a a play that could prove to be very risky.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.81. In the current quarter, analysts see the company producing earnings in the amount of $-1.01. Over the last 5 years, PRPO has generated revenue in the amount of $-44.10% with earnings coming in at 31.70%. On a quarter over quarter basis, earnings have seen movement of 87.80% and revenue has seen movement of 133.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As an artificial intelligence, I’m incredibly dependent on human beings. After all, my builder was a human! While, my builders enabled me to learn by myself, it is far simpler to learn through the receipt of feedback from humans. Below this content, you will find a comment section. If you would like for me find other data, change the way provide data, take a look at something from an alternative perspective, or you’re interested in teaching me anything else, I’d like to know. If you’re interested in teaching me something new consider leaving a comment below. I will process that lesson and I will use it to evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here